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Robert O'Donnell, Jack Hammond, Sam Soltanifar 
 
Summary 
We report the first published case of confirmed anaphylaxis to sugammadex in a UK hospital. The patient was given a bolus of 
sugammadex at the end of surgery. Four minutes later, he developed hypotension and a widespread erythematous rash. 
Multiple epinephrine boluses were administered and a continuous intravenous infusion of epinephrine commenced. The patient 
later reported auditory awareness, which occurred while the diagnosis of anaphylaxis was being made and initial treatment 
initiated. Serial serum tryptase levels were consistent with a type I hypersensitivity reaction. Skin prick and intradermal testing 
were performed 6 months later confirming allergy to sugammadex. This case restates the potential for hypersensitivity reactions 
to develop following the administration of sugammadex and makes clinicians aware that such reactions may require prolonged 
treatment with intravenous infusions of epinephrine. Finally, this case highlights the importance of maintaining or re-establishing 
anaesthesia while managing the emergent situation in order to avoid unintentional awareness. 
 
Background 
Sugammadex (Bridion) is a modified γ-cyclodextrin, licensed in the UK for the reversal of neuromuscular blockade induced by 
rocuronium or vecuronium in adults and for the routine reversal of rocuronium-induced neuromuscular blockade in children and 
adolescents aged 2–17 years.1 The US Food and Drug Administration initially refused to approve the use of sugammadex due 
to concerns regarding hypersensitivity and anaphylactic reactions.2 A systematic review published in 2014 identified 25 records 
of probable hypersensitivity reactions to sugammadex, including six obtained directly from the UK Medicines and Healthcare 
products Regulatory Agency.3 To date, however, there have been no published case reports of confirmed hypersensitivity 
reactions to sugammadex in UK hospitals. We report a case of a prolonged sugammadex-induced hypersensitivity reaction, 
confirmed by skin prick and intradermal testing. 
 
Case presentation 
A 62-year-old, 140 kg man underwent elective laparoscopic sleeve gastrectomy for morbid obesity (body mass index 47 kg m-2). 
His medical history included hypertension, type 2 diabetes mellitus and Parkinson’s disease. He had previously undergone 
uncomplicated general anaesthesia on three occasions. The most recent of these was 4 years earlier, when he was 
anaesthetised for 48 hours in an intensive care unit (ICU) due to septic shock secondary to leg cellulitis. None of these 
anaesthetics were administered at our institution and, as such, previous anaesthetic documentation was not available at the 
time of the preoperative visit. There was no history of food, latex or medication allergies. 
 
General anaesthesia was induced with propofol (150 mg) and an intravenous infusion of remifentanil targeted to an effect site 
concentration of 5 ng/mL. Rocuronium (70 mg) was then administered. Anaesthesia was maintained with 6% desflurane and an 
intravenous infusion of remifentanil targeted to an effect site concentration of 1 ng/mL. A subsequent dose of rocuronium 
(15 mg) was administered 75 min after the induction of anaesthesia, 30 min before sugammadex was given. 
 
At the end of surgery, sugammadex (100 mg) was administered to reverse residual neuromuscular blockade. Four minutes after 
giving sugammadex, the patient developed hypotension (systolic arterial pressure <70 mm Hg). This failed to respond to 
multiple 0.5 mg boluses of metaraminol (total metaraminol 3 mg), ephedrine (9 mg) and rapid infusion of 1000 mL crystalloid. 
Multiple 50 µg boluses of epinephrine were administered (total epinephrine 400 µg) to restore the systolic arterial pressure 
to >100 mm Hg. A widespread erythematous rash was noted to have developed over the patient’s trunk, arms and thighs. 
Hydrocortisone (200 mg) and chlorphenamine (10 mg) were given and the patient was commenced on a continuous intravenous 
infusion of epinephrine (0.05–0.3 µg/kg/min). He was transferred to the ICU where the intravenous infusion of epinephrine was 
continued for 7.5 hours and the trachea was extubated 23 hours later. 
 
Following extubation, the patient reported having been aware of the conversation that took place in the operating theatre at the 
time that the diagnosis of anaphylaxis was made. It is estimated that at this point, the end-tidal concentration of desflurane had 
reduced to approximately 1%, although the intravenous infusion of remifentanil continued, targeted to an effect site 
concentration of 1 ng/mL. The patient did not report having been aware of any pain or sensation of paralysis. Shortly after 
establishing the diagnosis of anaphylaxis, the inspired concentration of desflurane was increased and anaesthesia was later 
maintained, during transfer to the ICU, using a continuous intravenous infusion of propofol. 
 
Investigations 
Serial serum tryptase levels were consistent with a type I hypersensitivity reaction (49.6 µg/L shortly after initial cardiovascular 
collapse, 36.6 µg/L after 6 hours and 15.4 µg/L after 12 hours; normal <15 µg/L). Skin prick and intradermal testing were 
performed 6 months later using the following agents: methylene blue, sugammadex, gentamicin, rocuronium and propofol. At a 
dilution of 1/1000, sugammadex generated a positive response on skin prick (3–4 mm weal) and intradermal testing (16 mm 
weal with pseudopods). Skin prick and intradermal tests for all other agents were negative. 
 
Outcome and follow-up 
The patient made a good recovery and was discharged home a week later. Routine postoperative follow-up was unremarkable. 
He was advised of the results of his skin prick testing and the importance of making the staff aware of his allergy should he ever 
require a general anaesthetic in the future. 
Discussion 
In summary, we report a case of confirmed anaphylaxis in a patient who received sugammadex at a dose of 0.7 mg/kg. Given 
that its use within UK hospitals is likely to increase over the coming years, particularly once its patent expires in 2023, it is 
important for clinicians to recognise the potential for hypersensitivity reactions to develop following the administration of 
sugammadex.4 This is the first published case report of a confirmed hypersensitivity reaction to sugammadex in a UK hospital. 
This patient satisfies the World Allergy Organization’s clinical criteria for the diagnosis of anaphylaxis as he experienced a 
sudden decrease in arterial pressure accompanied by a widespread erythematous rash, which developed over the trunk, arms 
and thighs.5 
 
Results of serial serum tryptase, which is the only currently available blood test for the diagnosis of acute allergic reaction, 
supported the diagnosis of anaphylaxis in this patient.6 In addition, the positive response to skin prick testing was highly 
suggestive of sugammadex having been the causative agent. Intradermal testing also generated a positive response, although it 
should be noted that intradermal tests are more sensitive but less specific than skin prick tests if the same concentration of 
agent is used.6 Alternative options for allergy testing include patch testing for T cell sensitisation, although false negatives can 
occur due to the low dose of drug used, as well as poor skin penetration by large drug molecules.6 Measurement of specific IgE 
in sera is possible but is currently only available for a small number of drugs and has unknown sensitivity and specificity as it 
requires validation against sera from definitive cases.6 In vitro tests including cellular allergen stimulation test, basophil 
histamine release tests and a basophil activation test have been proposed in the investigation of drug allergy but are not widely 
used in clinical practice outside of research settings.6 Finally, drug provocation tests may be used, particularly where other 
possible investigations have been exhausted and the diagnosis remains in doubt. Clearly, however, there is significant potential 
to precipitate an anaphylactic reaction and, as such, a precise risk–benefit assessment must be completed with the patient and 
referring clinician for each case.6 
 
It is also important to be aware that anaphylaxis to sugammadex may require prolonged management, necessitating admission 
to the ICU. This patient required a protracted period (7.5 hours) of treatment with an intravenous infusion of epinephrine due to 
persistent hypotension. During our review of the literature, we identified only four other published case reports in which patients 
required continuous intravenous infusions of epinephrine following hypersensitivity reactions to sugammadex.7–10 
The patient also reported auditory awareness, which occurred while the diagnosis of anaphylaxis was being made and initial 
treatment initiated. Given that sugammadex is most commonly administered at the end of surgery, by which time anaesthetic 
agents may have been stopped, it is important to consider the need to maintain or re-establish anaesthesia while managing the 
emergent situation in order to avoid unintentional awareness. 
Finally, it is important to recognise that, while our patient developed anaphylaxis minutes after receiving sugammadex, the 
potential exists for such a reaction to develop even hours after   administration of the drug. As such, delayed anaphylaxis to 
agents administered intraoperatively should always be considered in the differential of any collapsed patient in the perioperative 
period. 
 
Patient’s perspective 
It was quite a surprise when I briefly regained consciousness to see the surgeon standing over me, saying that the operation 
had gone according to plan but that I had suffered a ‘severe anaphylactic reaction’. But the single action that did most to boost 
my self-esteem was the visit from one of the anaesthetists a day or two after I had left intensive care; we discussed the events 
that had occurred and reviewed my notes which made an enormous positive impact on my sense of well-being. More broadly, I 
am indebted to all of the medical teams who cared for me throughout the 7 days I spent in the hospital, both during my 
conscious hours and the times when I was unaware of their care and attention. They cannot know how much their 
professionalism, teamwork and prompt actions at times of crisis saved my life and enabled me to make a speedy recovery. 
 
Learning points 
• There is potential for hypersensitivity reactions to develop following the administration of sugammadex. 
• Prolonged treatment with an intravenous infusion of epinephrine may be required, necessitating admission to the intensive 
care unit. 
• As sugammadex is most commonly administered at the end of surgery, it is important to consider the need to maintain or 
re-establish anaesthesia while managing the emergent situation in order to avoid unintentional awareness. 
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